[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"clopidogrel-resistance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:clopidogrel-resistance":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100581686","phase-3-precision-antiplatelet-therapy-guided-by-platelet-aggregation-function-in-patients-with-acute-ischemic-stroke-100581686",false,"NCT06853535","Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE","PATH STROKE C","Inclusion Criteria:\n\n1. Age ≥ 18 years old.\n2. Patients diagnosed with acute non-disabling ischaemic stroke or transient ischaemic attack (TIA) with moderate to high stroke risk in accordance with the WHO diagnostic criteria, defined as follows:\n\n   * Acute non-disabling ischaemic stroke: NIHSS score ≤ 5 at enrollment;\n   * TIA with moderate to high stroke risk: ABCD₂ score ≥ 4.\n3. Time from symptom onset ≤ 48 hours. (Definition of symptom onset time: the interval from the last time the patient was observed in a normal state to the time of co-administration of clopidogrel 300 mg and aspirin 100 mg.)\n4. MARADP ≥ 35% measured at 5-20 hours after the patient received antiplatelet therapy with co-administration of clopidogrel 300 mg and aspirin 100 mg within 48 hours of symptom onset.\n5. Written informed consent signed by the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Imaging examinations suggestive of hemorrhagic stroke, hemorrhagic transformation, or other pathological cerebral disorders, such as vascular malformation, tumor, abscess, or other common non-ischemic cerebral diseases (e.g., multiple sclerosis).\n2. Minor stroke\u002FTIA induced by angioplasty or vascular surgery.\n3. Routine electrocardiogram (ECG) suggestive of atrial fibrillation (AF), or physical examination findings of typical AF signs including completely irregular cardiac rhythm, variable intensity of the first heart sound, and pulse deficit.\n4. Having definite indications for anticoagulant therapy (suspected cardiogenic embolism, e.g., atrial fibrillation, known artificial heart valve, suspected endocarditis, etc.).\n5. Patients who have received intravenous thrombolysis, intra-arterial thrombolysis, mechanical thrombectomy, or any revascularization surgery after the current onset, or plan to receive such procedures within 90 days.\n6. Use of antiplatelet agents other than aspirin and clopidogrel (e.g., ticagrelor, prasugrel) within 7 days.\n7. History of gastrointestinal bleeding, intracranial hemorrhage, massive hemorrhage or blood transfusion in the recent period (excluding mild hemoptysis and mild abnormal vaginal bleeding), or history of other hemorrhagic diseases caused by coagulation dysfunction (e.g., purpura).\n8. Having contraindications to or intolerance of clopidogrel, ticagrelor, or aspirin, including:\n\n   * Known history of hypersensitivity;\n   * Severe hepatic or renal insufficiency (definition of severe hepatic insufficiency: ALT \\> 2× upper limit of normal \\[ULN\\] or AST \\> 2× ULN; definition of severe renal insufficiency: creatinine \\> 1.5× ULN);\n   * Severe heart failure (NYHA Class Ⅲ or Ⅳ);\n   * Coagulation disorders or history of systemic hemorrhage;\n   * History of previous thrombocytopenia or neutropenia;\n   * History of previous drug-induced hematological diseases or hepatic dysfunction.\n9. Leukopenia (\\\u003C 2×10⁹\u002FL) or thrombocytopenia (\\\u003C 100×10⁹\u002FL).\n10. Use of heparin or oral anticoagulants within 10 days prior to enrollment.\n11. Patients with severe cardiac, pulmonary, hepatic, or renal insufficiency, and those with severe comorbidities (e.g., malignancy, chronic airflow limitation, severe dementia, severe heart failure).\n12. Women of childbearing age with a negative pregnancy test but who refuse to adopt effective contraceptive measures; pregnant or lactating women.\n13. Poor compliance, unable to cooperate with the requirements of the study.","ALL","18 Years",{"count":19,"type":20},5138,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The objective of this clinical trial is to evaluate the efficacy and safety of platelet aggregation function - guided precision anti - platelet therapy in patients with acute cerebral infarction. The main question it aims to answer is: among the cerebral infarction patients with possible clopidogrel resistance detected by platelet aggregation function tests, what is the efficacy and safety of using ticagrelor to replace the clopidogrel treatment regimen.",[26,27],"Acute Ischemic Stroke","Clopidogrel Resistance","RECRUITING","2026-05-11",{"date":31,"type":32},"2026-05-12","ACTUAL",{"date":34,"type":32},"2025-05-23",{"date":36,"type":20},"2027-12-31",{"name":38,"class":39},"Sichuan Provincial People's Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100573966","evaluation-of-the-efficacy-of-novel-biomarkers-in-predicting-clopidogrel-resistance-in-patients-with-ischemic-stroke-100573966","NCT06753149","Evaluation of the Efficacy of Novel Biomarkers in Predicting Clopidogrel Resistance in Patients with Ischemic Stroke","Clinical Application Research and Evaluation of Biomarkers Predicting Clopidogrel Resistance in Patients with Ischemic Stroke","Inclusion Criteria:\n\n* Age range: 18-80 years old. Within 72 hours after symptom onset (admission), the patient has started receiving \"standard\" antiplatelet therapy (which must include Plavix, taken alone or in combination)\n* Diagnosed with mild, non cardiogenic, non disabling AIS (NIHSS score ≤ 3) or high-risk TIA (ABCD2 stroke risk assessment ≥ 4) based on the patient's symptoms, signs (such as hemiplegia, hemianopia, hemiparesis, aphasia, etc.) and various routine diagnoses and tests (including but not limited to neuroimaging, such as cranial CT, MRI, Doppler, etc.)\n\nExclusion Criteria:\n\n* 72 hours after the onset of symptoms (admission), the patient began receiving \"standard\" antiplatelet therapy (including polivix, taken alone or in combination) for moderate or severe AIS (NIHSS score ≥ 5)\n* Patients who require intravenous thrombolysis (using rt PA, urokinase, alteplase, or tiniprase, etc.)\n* Mechanical intervention for thrombectomy\n* Cardiogenic AIS (with concomitant atrial fibrillation)\n* Embolic stroke of unknown origin (ESUS)\n* Perioperative stroke\n* Use anticoagulant drugs (such as warfarin, rivaroxaban, dabigatran etexils, etc.)\n* Individuals with severe liver and kidney dysfunction\n* Individuals allergic to clopidogrel or aspirin\n* Individuals with a tendency towards bleeding (such as low platelet count or active gastric or intestinal ulcers)\n* Individuals with a history of easy miscarriage or who are currently pregnant\n* Patients with malignant tumors or life expectancy of less than 1 year","80 Years",{"count":50,"type":20},800,"OBSERVATIONAL","The goal of this observational study is to explore the potential efficacy of related biomakers in predicting clopidogrel resistance in patients with ischemic stroke. To be specific :\n\n1. To investigate the relationship between the changes in ADP induced platelet aggregation rate, human plasma C4BPα concentration, mRNA expression levels of mARC1 and ABCC3-013 (splicing variant) in peripheral blood leukocytes, and the changes in the mRNA expression levels of ABCC3-013 (splicing variant) in selected hospitalized patients before and on the 3rd and 7th day after antiplatelet therapy, as well as on the 30th and 90th day after follow-up, in accordance with the current guidelines for secondary stroke prevention, and to explore the relative efficacy of each biomarker in predicting clopidogrel resistance;\n2. To collect blood samples from patients, extract their DNA samples, perform CYP2C19 genotyping, validate and evaluate the predictive efficacy and clinical application value of a biomarker \"panel\" composed of multiple new and old biomarkers for predicting clopidogrel resistance.",[54,55,27],"Ischemic Stroke","TIA (Transient Ischemic Attack)","NOT_YET_RECRUITING","2024-12-23",{"date":59,"type":32},"2024-12-31",{"date":61,"type":20},"2025-02-01",{"date":63,"type":20},"2026-03-31",{"name":65,"class":39},"Nanjing First Hospital, Nanjing Medical University"]